| Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia I Antony-Debré, VT Manchev, N Balayn, D Bluteau, C Tomowiak, ... Blood, The Journal of the American Society of Hematology 125 (6), 930-940, 2015 | 117 | 2015 |
| Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia M Mahévas, M Gerfaud-Valentin, G Moulis, L Terriou, S Audia, S Guenin, ... Blood, The Journal of the American Society of Hematology 128 (12), 1625-1630, 2016 | 90 | 2016 |
| TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia S Poulain, C Roumier, E Bertrand, A Renneville, A Caillault-Venet, ... Clinical Cancer Research 23 (20), 6325-6335, 2017 | 74 | 2017 |
| Long‐term follow‐up and second malignancies in 487 patients with hairy cell leukaemia E Cornet, C Tomowiak, A Tanguy‐Schmidt, S Lepretre, J Dupuis, ... British journal of haematology 166 (3), 390-400, 2014 | 65 | 2014 |
| Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia … E Durot, C Tomowiak, AS Michallet, J Dupuis, B Hivert, S Leprêtre, ... British Journal of Haematology 179 (3), 439-448, 2017 | 51 | 2017 |
| Humoral response to mRNA anti–COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia C Bagacean, R Letestu, C Al-Nawakil, S Brichler, V Lévy, N Sritharan, ... Blood advances 6 (1), 207-211, 2022 | 47 | 2022 |
| The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation M d'Aveni, L Aïssi-Rothé, V Venard, A Salmon, A Falenga, V Decot, ... Transplant Immunology 24 (4), 224-232, 2011 | 41 | 2011 |
| Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up J Paillassa, E Cornet, S Noel, C Tomowiak, S Lepretre, S Vaudaux, ... Blood Cancer Journal 10 (5), 62, 2020 | 40 | 2020 |
| Diagnosis and treatment of chronic lymphocytic leukemia: recommendations of the French CLL Study Group (FILO) A Quinquenel, T Aurran-Schleinitz, A Clavert, F Cymbalista, C Dartigeas, ... Hemasphere 4 (5), e473, 2020 | 39 | 2020 |
| Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The F rench intergroup experience LM Fornecker, T Aurran‐Schleinitz, AS Michallet, B Cazin, R Guieze, ... American Journal of Hematology 90 (6), 511-514, 2015 | 32 | 2015 |
| Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020 A Bobin, E Liuu, N Moya, C Gruchet, F Sabirou, A Lévy, H Gardeney, ... Cancers 12 (10), 2885, 2020 | 31 | 2020 |
| BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia C Herbaux, C Kornauth, S Poulain, SJF Chong, MC Collins, R Valentin, ... Blood, The Journal of the American Society of Hematology 137 (25), 3495-3506, 2021 | 27 | 2021 |
| Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia C Tomowiak, S Poulain, C Herbaux, A Perrot, B Mahé, P Morel, T Aurran, ... Blood Advances 5 (9), 2438-2446, 2021 | 26 | 2021 |
| Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm … AS Michallet, MS Dilhuydy, F Subtil, V Rouille, B Mahe, K Laribi, ... The Lancet Haematology 6 (9), e470-e479, 2019 | 25 | 2019 |
| Clinicopathological spectrum of renal parenchymal involvement in B-cell lymphoproliferative disorders V Javaugue, C Debiais-Delpech, M Nouvier, E Gand, S Chauvet, ... Kidney International 96 (1), 94-103, 2019 | 22 | 2019 |
| Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for waldenström's macroglobulinemia: a prospectively randomized trial of the european … C Buske, MA Dimopoulos, A Grunenberg, E Kastritis, C Tomowiak, ... Journal of Clinical Oncology 41 (14), 2607-2616, 2023 | 21 | 2023 |
| A prognostic index predicting survival in transformed Waldenström macroglobulinemia E Durot, L Kanagaratnam, S Zanwar, E Kastritis, S D’Sa, R Garcia-Sanz, ... haematologica 106 (11), 2940, 2021 | 19 | 2021 |
| Bortezomib in combination with dexamethasone, rituximab and cyclophosphamide (B-DRC) as first-line treatment of Waldenstrom's macroglobulinemia: results of a prospectively … C Buske, MA Dimopoulos, A Grunenberg, E Kastritis, C Tomowiak, ... Blood 136, 26, 2020 | 19 | 2020 |
| Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis J Broséus, S Hergalant, J Vogt, E Tausch, M Kreuz, A Mottok, C Schneider, ... Nature communications 14 (1), 309, 2023 | 17 | 2023 |
| Current treatment strategies in chronic myeloid leukemia F Guilhot, L Roy, C Tomowiak Current opinion in hematology 19 (2), 102-109, 2012 | 17 | 2012 |
